Page 1

August 12 , 2021 CORBUS PHARMACEUTICALS Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates • Company focused on gaining regulatory clarity for late - stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinic • Augmenting the pipeline through business development continues to bea priority • Cash and investments on hand of $ 114M provides projected runway into first quarter of 2024 Norwood , MA , Aug. 12 , 2021 ( GLOBE NEWSWIRE ) -- Corbus Pharmaceuticals Holdings , Inc. ( NASDAQ : CRBP ) ( “ Corbus ” or the “ Company ” ) , an immunology company , today provided corporate updates and reported financial results for the second quarter of 2021 . Corporate updates : • Lenabasum : The primary endpoint in the DETERMINE Phase 3 study of lenabasum in dermatomyositis was not met , although evidence of activity was seen in multiple endpoints . The next step for this program is to reach agreement with the FDA on the potential path forward in dermatomyositis . The company expects topline data from the National Institutes of Health - sponsored Phase 2 study of lenabasum systemic lupus erythematosus in Q4 2021 . in • Cannabinoid receptor type 1 ( CB1 ) program : Corbus ' CB1 inverse agonists are in preclinical development for treatment of metabolic diseases . In an animal model of diet - induced obesity , our most advanced candidate ( CRB - 556 ) generates weight loss as a monotherapy , and its combination with a GLP - 1 agonist resulted in greater weight loss than with the GLP - 1 inhibitor alone . Program is on track for IND in 2022 . • Cannabinoid receptor type 2 ( CB2 ) program : Corbus ' CB2 agonists are in preclinical development for treatment of cancer in combination with existing therapies , such as checkpoint inhibitors . Corbus compounds inhibit tumor cells proliferation in vitro and have activity as monotherapy in animal models of cancer . Key preclinical data are expected in Q3 2021 that will guide the path to an IND . • Anti - TGFẞ integrin monoclonal antibody ( mAb ) program : ■ New data demonstrate CRB - 601 is highly effective at inhibiting avẞ8 - mediated activation of diffusible and non - diffusible TGFẞ in vitro , has preliminary efficacy in the syngeneic animal model of lung cancer ( Lewis lung carcinoma model ) , and appears to be significantly more effective ( 75x ) in vitro than ADWA - 11 ( PF- 06940434 ) , an anti - avẞ8 mAb being tested in a Phase 1 study sponsored by